Trial Profile
A Prospective Observational Study of 1st and 2nd Line Vectibix Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors Amgen
- 13 Dec 2018 Status changed from active, no longer recruiting to completed.
- 01 Dec 2017 Planned End Date changed from 30 Dec 2018 to 30 Nov 2018.
- 01 Dec 2017 Planned primary completion date changed from 30 Dec 2018 to 30 Nov 2018.